Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

NCT05441488 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT05441488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05441488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
Lead sponsor
AB Science
Phase
Phase 3
Overall status
Suspended
Start date
June 28, 2022
Completion date
December 31, 2028
Enrollment
800 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

progressive multiple sclerosis